Titanovo Logo
Back to Cell Types

SCaBERHomo sapiens (Human)Cancer cell line

Also known as: Scaber, SCABER

🤖 AI SummaryBased on 16 publications

Quick Overview

Human bladder cancer cell line for research on urothelial carcinoma.

Detailed Summary

SCaBER is a human bladder cancer cell line derived from a squamous cell carcinoma of the urinary bladder. It is widely used in research for studying urothelial carcinoma, particularly in investigations related to genetic mutations, molecular pathways, and therapeutic responses. The cell line has been characterized for its chromosomal abnormalities, including deletions on chromosome 9p21, which affect genes such as CDKN2, CDKN2B, and MTAP. SCaBER is also noted for its utility in studying the role of TSC1 mutations and their implications in bladder cancer progression. Research involving SCaBER has contributed to understanding the molecular mechanisms underlying bladder cancer, including the identification of key genetic alterations and their impact on cell proliferation and drug sensitivity.

Research Applications

Genetic mutation analysisMolecular pathway investigationTherapeutic response studiesChromosomal abnormality characterization

Key Characteristics

Deletions on chromosome 9p21Inactivation of CDKN2, CDKN2B, and MTAP genesTSC1 mutationsUse in urothelial carcinoma research
Generated on 6/20/2025

Basic Information

Database IDCVCL_3599
SpeciesHomo sapiens (Human)
Tissue SourceUrinary bladder[UBERON:UBERON_0001255]

Donor Information

Age58
Age CategoryAdult
SexMale
Raceblack_or_african_american

Disease Information

DiseaseBladder squamous cell carcinoma
LineageBladder/Urinary Tract
SubtypeBladder Squamous Cell Carcinoma
OncoTree CodeBLSC

DepMap Information

Source TypeATCC
Source IDACH-000839_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg110Leu (c.329G>T)Unspecified-PubMed=10741724, PubMed=7732013
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
11,13
D13S317
11,12
D16S539
11,12
D18S51
15
D19S433
10,13
D21S11
29,32.2
D2S1338
19,21
D3S1358
16
D5S818
12,13
D7S820
8,10
D8S1179
13,14
FGA
22,23
Penta D
3.2,5
Penta E
7,9
TH01
7,9
TPOX
9,11
vWA
16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Systematic review: characteristics and preclinical uses of bladder cancer cell lines.

Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.

Bladder Cancer 4:169-183(2018).

DOIPubMedPMC

Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.

Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.

Oncogene 36:35-46(2017).

DOIPubMedPMC

The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Chanock S.J., Valencia A., Real F.X.

BMC Genomics 16:403.1-403.16(2015).

DOIPubMedPMC

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

Knowles M.A.

PLoS ONE 8:E84411-E84411(2013).

DOIPubMedPMC

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Hurst C.D., Platt F.M., Knowles M.A.

Eur. Urol. 65:367-369(2014).

DOIPubMed

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.

Eur. Urol. 65:360-366(2014).

DOIPubMed

TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.

Kwiatkowski D.J.

J. Pathol. 230:17-27(2013).

DOIPubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization.

Young B.D., Oliver R.T.D.

Cancer Genet. Cytogenet. 135:139-146(2002).

DOIPubMed

Short tandem repeat profiling provides an international reference standard for human cell lines.

Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).

DOIPubMedPMC

Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.

Markl I.D.C., Jones P.A.

Cancer Res. 58:5348-5353(1998).

PubMed

The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.

Stadler W.M., Olopade O.I.

Urol. Res. 24:239-244(1996).

DOIPubMed

Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.

Singh S.V., Xu B.H., Gupta V., Emerson E.O., Zaren H.A., Jani J.P.

Cancer Lett. 95:49-56(1995).

DOIPubMed

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

Wright W.C., Daniels W.P., Fogh J.

J. Natl. Cancer Inst. 66:239-247(1981).

DOIPubMed

Identity of some human bladder cancer cell lines.";

O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.

Nature 301:429-430(1983).

DOIPubMed

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).

DOIPubMedPMC

Human urologic cancer cell lines.";

Williams R.D.

Invest. Urol. 17:359-363(1980).

PubMed

Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.

Franks L.M.

Cancer Res. 46:3630-3636(1986).

PubMed

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

DOIPubMed

Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.

Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.

Am. J. Pathol. 119:361-366(1985).

PubMedPMC

A cell line (SCaBER) derived from squamous cell carcinoma of the human urinary bladder.

O'Toole C.M., Nayak S.K., Price Z.H., Gilbert W.H., Waisman J.

Int. J. Cancer 17:707-714(1976).

DOIPubMed

Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.

Fogh J.

Natl. Cancer Inst. Monogr. 49:5-9(1978).

PubMed

Web Resources

synapse.org